Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
CIPLA | AUROBINDO PHARMA | CIPLA/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 36.3 | 18.2 | 199.1% | View Chart |
P/BV | x | 4.2 | 3.9 | 106.8% | View Chart |
Dividend Yield | % | 0.5 | 0.3 | 181.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-20 |
AUROBINDO PHARMA Mar-19 |
CIPLA/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 586 | 830 | 70.5% | |
Low | Rs | 357 | 527 | 67.7% | |
Sales per share (Unadj.) | Rs | 207.0 | 333.9 | 62.0% | |
Earnings per share (Unadj.) | Rs | 18.6 | 40.4 | 46.1% | |
Cash flow per share (Unadj.) | Rs | 33.2 | 51.8 | 64.1% | |
Dividends per share (Unadj.) | Rs | 4.00 | 2.50 | 160.0% | |
Dividend yield (eoy) | % | 0.8 | 0.4 | 230.4% | |
Book value per share (Unadj.) | Rs | 195.5 | 237.1 | 82.5% | |
Shares outstanding (eoy) | m | 806.35 | 585.91 | 137.6% | |
Bonus/Rights/Conversions | ESOS | ESOP | - | ||
Price / Sales ratio | x | 2.3 | 2.0 | 112.0% | |
Avg P/E ratio | x | 25.3 | 16.8 | 150.7% | |
P/CF ratio (eoy) | x | 14.2 | 13.1 | 108.4% | |
Price / Book Value ratio | x | 2.4 | 2.9 | 84.2% | |
Dividend payout | % | 21.5 | 6.2 | 347.2% | |
Avg Mkt Cap | Rs m | 379,912 | 397,569 | 95.6% | |
No. of employees | `000 | 25.8 | 17.9 | 144.7% | |
Total wages/salary | Rs m | 30,270 | 25,849 | 117.1% | |
Avg. sales/employee | Rs Th | 6,459.6 | 10,956.9 | 59.0% | |
Avg. wages/employee | Rs Th | 1,171.2 | 1,447.7 | 80.9% | |
Avg. net profit/employee | Rs Th | 580.2 | 1,324.3 | 43.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,949 | 195,636 | 85.3% | |
Other income | Rs m | 3,442 | 1,553 | 221.6% | |
Total revenues | Rs m | 170,391 | 197,189 | 86.4% | |
Gross profit | Rs m | 32,060 | 39,519 | 81.1% | |
Depreciation | Rs m | 11,747 | 6,680 | 175.9% | |
Interest | Rs m | 1,974 | 2,626 | 75.2% | |
Profit before tax | Rs m | 21,782 | 31,767 | 68.6% | |
Minority Interest | Rs m | -475 | 27 | -1,757.8% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
Tax | Rs m | 6,312 | 7,269 | 86.8% | |
Profit after tax | Rs m | 14,995 | 23,645 | 63.4% | |
Gross profit margin | % | 19.2 | 20.2 | 95.1% | |
Effective tax rate | % | 29.0 | 22.9 | 126.7% | |
Net profit margin | % | 9.0 | 12.1 | 74.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 117,038 | 153,645 | 76.2% | |
Current liabilities | Rs m | 43,931 | 120,429 | 36.5% | |
Net working cap to sales | % | 43.8 | 17.0 | 257.9% | |
Current ratio | x | 2.7 | 1.3 | 208.8% | |
Inventory Days | Days | 96 | 135 | 70.8% | |
Debtors Days | Days | 85 | 64 | 133.6% | |
Net fixed assets | Rs m | 107,424 | 103,909 | 103.4% | |
Share capital | Rs m | 1,613 | 586 | 275.2% | |
"Free" reserves | Rs m | 156,018 | 138,322 | 112.8% | |
Net worth | Rs m | 157,630 | 138,908 | 113.5% | |
Long term debt | Rs m | 23,693 | 1,800 | 1,316.6% | |
Total assets | Rs m | 236,626 | 264,544 | 89.4% | |
Interest coverage | x | 12.0 | 13.1 | 91.9% | |
Debt to equity ratio | x | 0.2 | 0 | 1,160.3% | |
Sales to assets ratio | x | 0.7 | 0.7 | 95.4% | |
Return on assets | % | 7.2 | 9.9 | 72.2% | |
Return on equity | % | 9.5 | 17.0 | 55.9% | |
Return on capital | % | 12.8 | 23.8 | 53.9% | |
Exports to sales | % | 33.0 | 49.6 | 66.6% | |
Imports to sales | % | 0 | 18.8 | 0.0% | |
Exports (fob) | Rs m | 55,175 | 97,091 | 56.8% | |
Imports (cif) | Rs m | NA | 36,741 | 0.0% | |
Fx inflow | Rs m | 56,036 | 97,316 | 57.6% | |
Fx outflow | Rs m | 6,764 | 40,589 | 16.7% | |
Net fx | Rs m | 49,272 | 56,727 | 86.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 30,685 | 16,220 | 189.2% | |
From Investments | Rs m | 1,040 | -28,768 | -3.6% | |
From Financial Activity | Rs m | -29,488 | 19,191 | -153.7% | |
Net Cashflow | Rs m | 2,340 | 6,656 | 35.2% |
Indian Promoters | % | 16.0 | 54.1 | 29.6% | |
Foreign collaborators | % | 20.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 12.2 | 8.0 | 153.5% | |
FIIs | % | 23.7 | 27.7 | 85.6% | |
ADR/GDR | % | 1.1 | 0.0 | - | |
Free float | % | 26.2 | 10.2 | 256.9% | |
Shareholders | 161,166 | 69,601 | 231.6% | ||
Pledged promoter(s) holding | % | 0.0 | 8.6 | - |
Compare CIPLA With: BIOCON CADILA HEALTHCARE SUVEN LIFE SCIENCES DR. DATSONS LABS WOCKHARDT
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More